A 3-month open label, national, quality-of-life, and safety study with pimecrolimus cream, 1 percent in children (age 2-12 years) with atopic dermatitis
Latest Information Update: 01 Aug 2007
At a glance
- Drugs Pimecrolimus (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Novartis
- 01 Aug 2007 New trial record.